<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">TRPM4 protein expression in prostate cancer: a novel tissue biomarker associated with risk of biochemical recurrence following radical prostatectomy</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2015-11-21">21 November 2015</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Kasper</forename><surname>Berg</surname></persName>
						</author>
						<author>
							<persName><surname>Drimer</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Kasper</forename><surname>Drimer Berg</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Department of Urology</orgName>
								<orgName type="institution">Copenhagen Prostate Cancer Center</orgName>
								<address>
									<settlement>Rigshospitalet</settlement>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="institution">University of Copenhagen</orgName>
								<address>
									<settlement>Copenhagen</settlement>
									<country key="DK">Denmark</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Davide</forename><surname>Soldini</surname></persName>
							<affiliation key="aff8">
								<orgName type="department">Institute of Surgical Pathology</orgName>
								<orgName type="institution">University Hospital Zurich (USZ)</orgName>
								<address>
									<settlement>Zurich</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Maria</forename><surname>Jung</surname></persName>
							<affiliation key="aff9">
								<orgName type="department">Institute of Pathology</orgName>
								<orgName type="institution">University Hospital Bonn (UKB)</orgName>
								<address>
									<addrLine>Sigmund-Freud-Str. 25</addrLine>
									<postCode>53127</postCode>
									<settlement>Bonn</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Dimo</forename><surname>Dietrich</surname></persName>
							<affiliation key="aff9">
								<orgName type="department">Institute of Pathology</orgName>
								<orgName type="institution">University Hospital Bonn (UKB)</orgName>
								<address>
									<addrLine>Sigmund-Freud-Str. 25</addrLine>
									<postCode>53127</postCode>
									<settlement>Bonn</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Carsten</forename><surname>Stephan</surname></persName>
							<affiliation key="aff10">
								<orgName type="department">Department of Urology</orgName>
								<orgName type="institution">Charité University Hospital</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Klaus</forename><surname>Jung</surname></persName>
							<affiliation key="aff11">
								<orgName type="institution">Berlin Institute for Urologic Research</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Manfred</forename><surname>Dietel</surname></persName>
							<affiliation key="aff12">
								<orgName type="department">Institute of Pathology</orgName>
								<orgName type="institution">Charité University Hospital</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ben</forename><surname>Vainer</surname></persName>
							<affiliation key="aff13">
								<orgName type="department">Department of Pathology, Rigshospitalet</orgName>
								<orgName type="institution">University of Copenhagen</orgName>
								<address>
									<settlement>Copenhagen</settlement>
									<country key="DK">Denmark</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><forename type="first">Glen</forename><surname>Kristiansen</surname></persName>
							<email>glen.kristiansen@ukb.uni-bonn.de</email>
							<affiliation key="aff9">
								<orgName type="department">Institute of Pathology</orgName>
								<orgName type="institution">University Hospital Bonn (UKB)</orgName>
								<address>
									<addrLine>Sigmund-Freud-Str. 25</addrLine>
									<postCode>53127</postCode>
									<settlement>Bonn</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="department">Zurich Open Repository</orgName>
								<orgName type="institution">Archive University of Zurich University Library Strickhofstrasse 39</orgName>
								<address>
									<postCode>CH-8057</postCode>
									<settlement>Zurich www.zora.uzh.ch</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<orgName type="department">Davide ; Jung</orgName>
								<address>
									<addrLine>Maria ; Dietrich, Manfred ; Vainer</addrLine>
									<settlement>Soldini, Dimo, Stephan, Carsten, Klaus, Dietel, Ben, Kristiansen, Glen</settlement>
									<region>Jung</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff2">
								<orgName type="department">Zurich Open Repository and Archive</orgName>
								<orgName type="institution">University of Zurich ZORA URL</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff3">
								<orgName type="department" key="dep1">Institute of Pathology</orgName>
								<orgName type="department" key="dep2">Institute of Surgical Pathology</orgName>
								<orgName type="institution">University Hospital Bonn (UKB)</orgName>
								<address>
									<settlement>Bonn</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff4">
								<orgName type="institution">University Hospital Zurich (USZ)</orgName>
								<address>
									<settlement>Zurich</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff5">
								<orgName type="department">Institute of Pathology</orgName>
								<orgName type="institution">Charité University Hospital</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">TRPM4 protein expression in prostate cancer: a novel tissue biomarker associated with risk of biochemical recurrence following radical prostatectomy</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2015-11-21">21 November 2015</date>
						</imprint>
					</monogr>
					<idno type="MD5">B2E2B6A52D425504E9B650F572313521</idno>
					<idno type="DOI">10.1007/s00428-015-1880-y</idno>
					<note type="submission">Received: 8 April 2015 / Revised: 20 October 2015 / Accepted: 10 November 2015 /</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:09+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Immunohistochemistry</term>
					<term>Interobserver variation</term>
					<term>Prostate cancer</term>
					<term>Radical prostatectomy</term>
					<term>Tissue biomarker</term>
					<term>TRPM4 Abbreviation BR-free survival Biochemical recurrence free survival</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>BACKGROUND Transient receptor potential cation channel, subfamily M, member 4 (TRPM4) messenger RNA (mRNA) has been shown to be upregulated in prostate cancer (PCa) and might be a new promising tissue biomarker.</s><s>We evaluated TRPM4 protein expression and correlated the expression level with biochemical recurrence (BR) following radical prostatectomy (RP).</s><s>MATERIAL AND METHODS The study included 614 patients who had undergone RP.</s><s>TRPM4 immunohistochemical staining was performed on samples of benign tissue, tissue containing PIN glands and PCa tissue using a commercially available polyclonal antibody.</s><s>Staining intensity was recorded by two independent observers using a four-tired semi-quantitative grading system (0, 1+, 2+, 3+) converted into H-scores.</s><s>Interobserver agreement was calculated by linear weighted kappa statistics.</s><s>The association between staining intensity and BR was analysed using the Kaplan-Meier estimator and uni-and multiple Cox proportional hazard regression models.</s><s>RESULTS Significantly higher staining intensity was found in PCa glands compared to benign glands (p &lt; 0.001).</s><s>The concordance rate in TRPM4 staining intensities for benign, PIN and PCa tissue ranged from 86.0 to 91.5 %, corresponding to linear weighted kappa values of 0.566-0.789.</s><s>After adjusting for patient and tumour characteristics, patients with a higher staining intensity in PCa glands compared to matched benign glands and an H-score equal to or above the median had an increased risk of BR (HR 1.79-2.62;</s><s>p = 0.01-0.03</s><s>for the two observers) when compared to patients with a lower staining intensity.</s><s>CONCLUSIONS TRPM4 protein expression is widely expressed in benign and cancerous prostate tissue, with highest staining intensities found in PCa.</s><s>Overexpression of TRPM4 in PCa (combination of high staining intensity and a high H-score) is associated with increased risk of BR after RP.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Prostate cancer (PCa) is the most common newly diagnosed malignancy among men in western countries and is estimated to be the leading cause of male cancer deaths in Europe in 2014 only surpassed by lung cancer and colorectal cancer <ref type="bibr" target="#b0">[1]</ref>.</s><s>The course of the disease varies from entirely indolent to fatal even for organ-confined tumours <ref type="bibr" target="#b1">[2]</ref>.</s><s>Therefore, accurate and individual risk estimates based on patient and tumour characteristics are essential for treatment decisions.</s><s>Although most nomograms and risk stratifications incorporate patient and tumour characteristics including prostate-specific antigen (PSA), Gleason score (GS), and clinical or pathological tumour stage (reviewed in <ref type="bibr" target="#b2">[3]</ref>), they still have limitations in intercepting the heterogeneous course of the disease.</s><s>Therefore, it is of utmost importance to identify sensitive and specific tissue, serum and urine biomarkers if the concept of personalised medicine is to become everyday clinical practice <ref type="bibr" target="#b3">[4]</ref>.</s></p><p><s>A novel group of tissue biomarkers is the transient receptor potential (TRP) channel superfamily.</s><s>It consists of 28 cationpermeable transmembrane channels classified into six subfamilies: TRP canonical (TRPC), TRP vanilloid (TRPV), TRP melastatin (TRPM), TRP mucolipin (TRPML), TRP polycystin (TRPP) and TRP ankyrin (TRPA) <ref type="bibr" target="#b4">[5]</ref>.</s><s>TRP channels are activated by a variety of mechanical and chemical stimuli and are considered as polymodal sensors with impact on both physiological and pathological conditions <ref type="bibr" target="#b5">[6]</ref>.</s></p><p><s>Most but not all TRP channels function as Ca 2+ pathways, some of which are pathways for intracellular storage and release of Ca 2+ from various compartments ( r e v i e w e di n <ref type="bibr" target="#b6">[ 7]</ref>).</s><s>This can lead to alterations in intracellular Ca 2+ -levels and subsequent increased proliferation <ref type="bibr" target="#b7">[8]</ref> and change in cell differentiation and apoptosis <ref type="bibr" target="#b8">[9,</ref><ref type="bibr" target="#b9">10]</ref>.</s><s>As a consequence, differences in expression patterns of TRP channels may play a role in cancer progression <ref type="bibr" target="#b10">[11]</ref>.</s><s>The transient receptor potential cation channel, subfamily M, member 4 (TRPM4) is a nonselective cation channel activated by increased intracellular Ca 2+ concentrations.</s><s>Upon activation, Na + i sa l l o w e dt op a s st h r o u g h the channel, which, in contrast, is impermeable to Ca 2+ <ref type="bibr" target="#b11">[12]</ref>.</s><s>TRPM4 is widely expressed throughout different organs with the highest messenger RNA (mRNA) levels found in the intestine and prostate <ref type="bibr" target="#b12">[13]</ref>.</s><s>For almost a decade, it has been known that TRPM4 mRNA is upregulated in PCa compared to normal tissue <ref type="bibr" target="#b13">[14]</ref>.</s><s>However, the physiological role of TRPM4 in the prostate needs to be further elucidated.</s><s>Since our own expression data showed overexpression of TRPM4 in PCa, and since others have shown that knockdown of TRPM4 in HeLa cervical cancer cells is associated with significantly decreased proliferation and a lower fraction of cells entering the S-phase of the cell cycle <ref type="bibr" target="#b14">[15]</ref>, we hypothesised that TRPM4 might also be relevant in the biology of PCa and its expression conceivable associated with prognosis.</s></p><p><s>The aim of the present study was to confirm upregulation of expression of TRPM4, which we had found in an earlier study at mRNA level, at protein expression level by immunohistochemical (IHC) staining.</s><s>Furthermore, we analysed whether overexpression of TRPM4 protein is associated with an increased risk of biochemical recurrence (BR) in a large cohort of PCa patients who had undergone radical prostatectomy (RP).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Materials and methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patient cohort</head><p><s>The cohort consisted of a subset of 640 PCa patients, who underwent RP between 1999 and 2005 at the Charité University Hospital in Berlin, Germany.</s><s>Twenty-six patients were excluded prior to this study due to missing tumour glands in the tissue microarray (TMA) cores or insufficient IHC staining, leaving 614 patients for analysis.</s><s>The cohort and its demographics have previously been described <ref type="bibr" target="#b15">[16]</ref> and are presented in short in Table <ref type="table" target="#tab_0">1</ref>.</s><s>Clinical follow-up data were reviewed annually.</s><s>BR was defined as postoperative PSA increase exceeding 0.2 ng/ml.</s><s>The Ethics Committee of the Charité University Hospital has approved the use of the tissue for immunohistochemistry and molecular biological techniques (EA1/06/2004).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Construction of the tissue microarrays</head><p><s>As previously described, formalin-fixed paraffin-embedded tissue blocks from radical prostatectomy specimens were selected for construction of TMA <ref type="bibr" target="#b15">[16]</ref>.</s><s>All patients were represented by five cores, which included two cores of invasive PCa reflecting the primary and secondary Gleason pattern, if possible.</s><s>Moreover, for each patient, the TMA included one core of benign prostatic hyperplasia (BPH), normal tissue and prostatic intraepithelial neoplasia (PIN), respectively.</s><s>If PIN was not present in the RP specimen, another core of normal tissue was included.</s><s>All cores were 1.8 mm in diameter and were arranged in 40 TMA recipient paraffin blocks.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Immunohistochemistry</head><p><s>Tissue microarray sections, each 3-4-μm thick, were mounted on Super Frost slides (Menzel Gläser, Braunschweig, Germany).</s><s>For detection of TRPM4 expression, a commercially available antibody (goat polyclonal, G-20; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA, catalogue no.</s><s>sc-27540) was diluted 1:100.</s><s>The primary antibody was detected using the refined rabbit-anti-goat protocol on the Bond immunohistochemistry platform (Leica).</s><s>Antibody specificity was ascertained by pre-incubation with a 10 molar excess of its corresponding peptide (TRPM4 (G-20)P; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA, catalogue no.</s><s>sc-27540 (peptide), which nearly completely abolished immunoreactivity (Supplementary Fig. <ref type="figure" target="#fig_0">S1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Assessment of immunohistochemical stainings</head><p><s>Two independent observers (DS + KDB), both blinded to clinical parameters, biochemical outcomes and the scores of the other observer, evaluated the IHC staining.</s><s>A scoring sheet depicting typical examples of staining intensities was produced after observer 1 had scored the TMA slides.</s><s>Observer 2 used the identical scoring sheet to enhance the interobserver agreement.</s></p><p><s>For benign, PIN and cancerous glands, the TRPM4 staining intensity was scored separately using a four-tier semi-quantitative grading system: no staining (0), weakly positive (1+), moderately positive (2+) and strongly positive (3+).</s><s>Only plasma membrane and cytoplasmic staining were considered.</s><s>Furthermore, for malignant cores, the percentage of tumour cells expressing TRPM4 protein with a staining intensity of 0, 1+, 2+ and 3+ was recorded.</s><s>An H-score was derived from the semi-quantitative estimates of the immunostaining: TRPM4-PCa H-score=(% of cells with staining intensity 1)+2* (% of cells with staining intensity 2+)+3*(% of cells with staining intensity 3+) <ref type="bibr" target="#b16">[17]</ref>.</s><s>Thus, the H-score range is 0 to 300, where 0 equals all tumour cells stained negative (0), whereas 300 equals all tumour cells stained strongly positive (3+).</s><s>For interobserver statistical analyses, H-scores were divided into four categories: low intensity (0-50), low-moderate intensity (51-100), high-moderate intensity (101-150) and high intensity (151-300).</s><s>Furthermore, patients were dichotomised according to H-scores into 'high staining intensity' (H-score equal to or above median Hscore) and 'low staining intensity' (H-score bellow media nH -s c o r e ) .T oa l s od e t e c ts u b tle staining intensity differences, patients were furthermore dichotomised according to whether TRPM4 expression was higher in PCa glands compared to benign glands (TRPM4 overexpressed vs. TRPM4 not overexpressed).</s><s>Equal or less staining intensity in PCa glands was reported as 'TRPM4 not overexpressed', whereas higher staining intensity in PCa glands was recorded as 'TRPM4 overexpressed'.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p><s>Associations between TRPM4 expression (high staining intensity vs. low staining intensity) and demographic and clinical variables were analysed using Pearson's chi-square test for categorical variables and the Mann-Whitney U test for continuous variables.</s><s>Linear weighted Kappa statistics were used to compare interobserver agreement and Pearson's correlation was calculated to compare H-scores.</s><s>The Kaplan-Meier estimator and log-rank tests were used to analyse the association between TRPM4 expression levels and risk of BR following RP.</s><s>Moreover, univariate and multiple Cox proportional hazard regression models were performed with BR as outcome.</s><s>Tests for linearity and proportionality were performed using cumulative and Schoenfeld residuals under the assumption that no interaction between covariates exists.</s><s>Two-sided pvalues &lt;0.05 were considered significant.</s><s>Statistical analyses were performed using R (R Development Core Team, Vienna, Austria, http://www.R-project.org) and SPSS version 21 (SPSS, Armonk, NY, USA).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Immunoreactivity of TRPM4 in prostate tissues</head><p><s>TRPM4 showed a cytoplasmic expression pattern in benign and malignant tissues alike.</s><s>In benign glands, basal cells were labelled (Fig. <ref type="figure" target="#fig_0">1a</ref>), whereas secretory cells were negative.</s><s>In neoplastic cells of HGPIN, TRPM4 showed stronger staining, as Fig. <ref type="figure" target="#fig_0">1b</ref> illustrates.</s><s>Epithelia of invasive tumours showed the highest degree of TRMP4 immunoreactivity.</s><s>In the stroma, immunostaining of smooth muscle cells was noted but not semi-quantitatively evaluated.</s><s><ref type="table" target="#tab_1">2</ref>).</s><s>When H-scores were divided into four groups, the concordance between the observers was 60.1 % corresponding to a linear weighted Kappa value of 0.541 (95 % CI 0.489-0.592).</s><s>There was a significant and strong correlation between the two H-scores when analysed on a continuous scale (Pearson'sc o r r elation coefficient=0.775,</s><s>p&lt;0.001).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>TRPM4 protein expression in prostate cancer</head><p><s>Demographics and tumour characteristics of the patient population has previously been published <ref type="bibr" target="#b15">[16]</ref> and are listed in Table <ref type="table" target="#tab_0">1</ref>.</s><s>In total, 43 patients (7.0 %) had received gonadotropin-releasing hormone analogues before surgery at the discretion of the referring urologist.</s><s>Median time of treatment was 4 weeks (range 2-16 weeks).</s><s>The predominant TRPM4 intensity was 1+ for benign glands (84.4-89.3</s><s>%), PIN (73.4-76.4</s><s>%) and PCa glands (63.0-66.8</s><s>%) for both observers (Figs. <ref type="figure" target="#fig_1">1 and 2</ref>).</s><s>However, statistically significantly higher TRPM4 staining intensity was found in PCa glands compared to benign tissue and PIN (chisquare test for trend 50.81 and 126.54, respectively; 1 df; both p&lt;0.001).</s><s>In cancerous glands, a predominant TRPM4 intensity of 2+ and 3+ was found in 25.6-30.8</s><s>and 1.6-2.0</s><s>%, respectively.</s><s>Reflecting that the predominant TRPM4 No association between TRPM4 expression and patient or tumour characteristics (age, PSA, GS, pathological tumour stage, and resection margin status) was found (Table <ref type="table" target="#tab_2">3</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>TRPM4 protein expression and biochemical recurrence</head><p><s>PSA relapse-free survival time was available for 576 patients (93.8 %).</s><s>When dichotomising patients into 'TRPM4 overexpressed' vs. 'TRPM4 not overexpressed', there was no significant difference between the two groups in terms of risk of BR for the two observers (log-rank: p=0.05 and p= 0.66, respectively) (Supplementary Fig. <ref type="figure" target="#fig_1">S2a + b</ref>).</s><s>Although only statistically significant for observer 2, patients with 'high staining intensity' had an increased risk of BR compared to patients with 'low staining intensity' (log-rank: p=0.061 and p=0.015, respectively) (Supplementary Fig. <ref type="figure" target="#fig_1">S2c + d</ref>).</s></p><p><s>A combined three-tiered variable was created representing intrapersonal and interpersonal differences in TRPM4 expression.</s><s>Patients were characterised as either 'TRPM4 not overexpressed and H-score below median',o r'TRPM4 overexpressed or H-score equal to or above median',o r 'TRPM4 overexpressed and H-score equal to or above median'.</s><s>On the records of observer 1, the groups separated into three different courses of BR (log-rank: p=0.043), with patients characterised as 'TRPM4 overexpressed and H-score equal to or above median' having the shortest BR free survival (Fig. <ref type="figure">3a</ref>).</s><s>For observer 2, the 'TRPM4 not overexpressed and H-score below median' group showed the best BR free survival (Fig. <ref type="figure">3b</ref>), whereas the two other groups overlapped.</s><s>Correspondingly, no significant difference in disease course was observed between the groups (log-rank: p=0.15).</s><s>TRPM4 was entered into two univariate and multiple Cox proportional hazard regression models (model A and B) using the individual TRPM4 sum scores for observer 1 and 2, respectively.</s><s>In both models, TRPM4 overexpression in combination with high staining intensity (i.e.</s><s>TRPM4 overexpressed in PCa compared with benign tissue combined with an Hscore equal to or above median) was associated with an increased risk of BR (Table <ref type="table" target="#tab_3">4</ref>).</s><s>This remained statistically significant after adjusting for age, PSA, GS, pathological tumour stage, surgical margins and prior hormonal treatment (model A: HR 2.62; 95 % CI 1.26-5.42;</s><s>p=0.010; model B: HR 1.79; 95 % CI 1.06-3.04;</s><s>p=0.030).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>This is the first report on TRPM4 protein expression in prostate tissues using a large, well-characterised cohort of PCa patients who have undergone RP.</s><s>Our group has previously shown that TRPM4 mRNA is among the top upregulated transcripts in PCa <ref type="bibr" target="#b13">[14]</ref>, which is in line with other profiling studies <ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref>.</s><s>In the present paper, we used IHC to detect TRPM4 protein and found that it is commonly expressed in prostatic tissue.</s><s>Protein expression was predominantly low, although we demonstrated a significant trend for higher semiquantitative expression levels in PCa tissue compared to benign and PIN glands.</s><s>Although high TRPM4 expression as such was not found to be associated with BR, the combination of having high TRPM4 in PCa compared to matched benign tissue with an H-score equal to or above median appeared to be a strong predictive marker for BR.</s><s>This corresponded to a 1.8-2.6-fold</s><s>increased risk of BR after RP when compared to patients without high TRPM4 expression and a low H-score.</s><s>Interestingly, we found no associations between TRPM4 expression and tumour characteristics, indicating that TRPM4 is an independent prognostic marker.</s><s>This needs to be verified in future studies to clarify if TRPM4 might be a useful candidate as prognostic test for prostate cancer, which clearly cannot be based on a single retrospective study.</s></p><p><s>The TRPM4 protein consists of six transmembrane domains and forms a nonselective cation channel after assembly of four subunits upon activation, although the stoichiometry is not yet fully known (reviewed in <ref type="bibr" target="#b11">[12]</ref>).</s><s>The channel is activated by Ca 2+ <ref type="bibr" target="#b20">[21]</ref><ref type="bibr" target="#b21">[22]</ref><ref type="bibr" target="#b22">[23]</ref>, has the highest permeability for Na + and K + , and is practically impermeable to Ca 2+ and Mg 2+ <ref type="bibr" target="#b20">[21,</ref><ref type="bibr" target="#b22">23,</ref><ref type="bibr" target="#b23">24]</ref>.</s><s>It has previously been demonstrated that TRPM4 mRNA is widely expressed in numerous types of tissue, the highest mRNA transcript levels being found in the prostate and the intestines <ref type="bibr" target="#b12">[13]</ref>.</s><s>Whereas the physiological function of TRPM4 in the prostate is unknown, it is involved in such diverse functions as depolarisation of vascular smooth muscle cells <ref type="bibr" target="#b24">[25]</ref>, regulation of sinus rhythm of the heart <ref type="bibr" target="#b25">[26]</ref> and the process of cell death through Na + influx <ref type="bibr" target="#b26">[27]</ref>.</s><s>Furthermore, TRPM4 expression is upregulated in an aggressive form of large B-cell non-Hodgkin lymphoma <ref type="bibr" target="#b27">[28]</ref>, and high expression has been found to correlate with tumour progression and metastatic disease <ref type="bibr" target="#b17">[18,</ref><ref type="bibr" target="#b27">28]</ref>.</s></p><p><s>In a recent study by Armisén et al., knockdown of TRPM4 with shRNA in HeLa cervical cancer cells was shown to significantly decrease proliferation, increase the fraction of cells in the G1 phase of the cell cycle and decrease the fraction of cells entering the S phase <ref type="bibr" target="#b14">[15]</ref>.</s><s>The authors further demonstrated that knockdown of TRPM4 results in decreased expression of cyclin D1, which is essential for the transition from G1 to S phase, decreased expression of survivin, a protein involved in progression of mitosis and resistance to apoptosis, as well as a decreased expression of β-catenin.</s><s>In the absence of Wnt signalling, cytoplasmic β-catenin is phosphorylated by glycogen synthase kinase 3β for degradation, whereas Wnt signalling promotes translocation of β-catenin to the nucleus, which transactivates various genes associated with proliferation and cell survival (reviewed in <ref type="bibr" target="#b28">[29,</ref><ref type="bibr" target="#b29">30]</ref>).</s><s>Indeed, Armisén et al. found that β-catenin is primarily located in the cytoplasm after TRPM4 knockdown, compared to its nuclear location in TRPM4 expressing HeLa cells.</s><s>The authors conclude that TRPM4 exerts its effects through inhibition of degradation of β-catenin, leading to nuclear translocation and increased cell proliferation <ref type="bibr" target="#b14">[15]</ref>.</s><s>In line with our results, this suggests that a high level of TRPM4 in a cancer is associated with a more aggressive course.</s></p><p><s>Most changes involving TRP proteins is caused by increased or decreased expression of the normal protein rather than mutations, and several members of the TRP superfamily show altered expression in cancer cells <ref type="bibr" target="#b10">[11]</ref>.</s><s>Previous studies on PCa have mainly focused on TRPM8 and TRPV6.</s><s>Although the published results are conflicting, significantly higher expression levels of T R P M 8m R N Ah a v eb e e nf o u n di nP C ai nc o m p a r i s o n to benign tissue <ref type="bibr" target="#b30">[31]</ref>.</s><s>However, higher TRPM8 levels were found to be inversely correlated to GS and tumour stage, although not statistically significant <ref type="bibr" target="#b31">[32]</ref>.</s><s>Additionally, low levels of TRPM8 mRNA expression were associated with a significant shorter time to BR following RP <ref type="bibr" target="#b32">[33]</ref>.</s><s>Hence, it seems as if expression level of TRPM8 is higher in PCa compared to benign tissue, but lower in aggressive PCa.</s><s>For TRPV6, normal epithelial cells and BPH tissue show mRNA expression, but interestingly, a higher expression level is found in PCa tissue with a positive correlation with GS and pathological tumour stage <ref type="bibr" target="#b33">[34,</ref><ref type="bibr" target="#b34">35]</ref>.</s></p><p><s>The present study has several limitations.</s><s>First, we used BR as the endpoint in the Kaplan-Meier and the Cox proportional hazard regression analyses.</s><s>Although BR is a widely used surrogate endpoint, it is well-known that a large proportion of patients will not develop symptoms, metastasis let alone PCa-related death even 10-15 years after BR, even if they do not receive adjuvant or salvage therapy <ref type="bibr" target="#b35">[36]</ref>.</s><s>Secondly, in most patients, PCa is a multifocal disease, and both intrafocal and interfocal heterogeneity are critical issues and limitations when studying tissue biomarkers, i.e. the accuracy of the IHC results might be limited by variations in expression patterns within and between tumour foci.</s><s>Indeed, intrafocal and interfocal staining heterogeneity for TRPM4 was observed for up to 97 % of the patients in the present study.</s><s>To minimise the impact of this heterogeneity, we used two TMA cores per patient reflecting the primary and secondary Gleason pattern, respectively, and calculated an H-score for each patient.</s><s>It might be argued, however, that two cores is insufficient to fully elucidate heterogeneity <ref type="bibr" target="#b36">[37]</ref>.</s><s>Thirdly, semi-quantitative IHC grading will inherently result in interobserver variation <ref type="bibr" target="#b37">[38]</ref>.</s><s>Before introducing a new biomarker, it is essential to acknowledge this drawback and moreover comprehend that semi-quantitative grading is affected by subjectivity and indeed is only semi-quantitative.</s><s>TRPM4 expression is not specific to epithelial cells but was also observed in stromal cells, which can impede accurate reading and might negatively influence interobserver agreement.</s><s>In the present study, we attempted to minimise the interobserver variation by creating a TRPM4 scoring sheet, which resulted in approximately 90 % concordance rates indicating moderate to substantial agreement according to the weighted kappa values <ref type="bibr" target="#b38">[39]</ref>.</s></p><p><s>Finally, this study lacks an independent validation cohort to confirm the potential of TRPM4 as a prognostic biomarker, which was, however, not the primary aim of this study.</s><s>Strengths of the present study are the large wellcharacterised cohort of PCa patients, the long-term followup and the inclusion of two independent observers.</s><s>TRP channels might be targets for management of cancer using potent channel inhibitors or using the TRP proteins as recognition sites for antibody-mediated toxic entry (reviewed in <ref type="bibr" target="#b10">[11]</ref>).</s><s>While the channel might be a suitable and attractive pharmacological target, blocking the channel might lead to serious adverse events due to the wide distribution of the protein.</s><s>Indeed, TRPM4 knockdown mice are characterised by mild hypertension, increased risk of anaphylaxis and increased risk of death in case of sepsis <ref type="bibr" target="#b11">[12]</ref>.</s><s>Thus, at the moment, TRPM4 does not seem to be a suitable pharmacological target for management of PCa but seems to provide important prognostic information in terms of risk of BR following RP.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusions</head><p><s>We show that TRPM4 protein is widely expressed in benign prostate tissue, PIN glands and cancerous glands with highest scoring intensities in PCa.</s><s>TRPM4 expression can be reliably visualised using IHC staining with a commercial available polyclonal antibody.</s><s>Moreover, the use of a scoring sheet resulted in substantial agreement in TRPM4 staining intensity scores between two observers.</s><s>Finally, the combination of TRPM4 overexpression in PCa in comparison to matched benign glands and an H-score equal to or above the median was independently associated with an increased risk of BR following RP, which warrants further study.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1</head><label>1</label><figDesc><div><p><s>Fig.1TRPM4 Immunohistochemistry in prostate tissues.</s><s>a TMPM4 is only very weakly expressed in secretory epithelium of benign glands, whereas basal cells show a weak to moderate labelling.</s><s>b Secretory epithelium of high grade PIN glands often shows an upregulation of TRPM4 staining.</s><s>c Prostate carcinoma with Gleason Score 3+3=6 without TRPM4 expression.</s><s>Adjacent myocytes of the stroma serve as an internal positive control.</s><s>d-f Prostate cancer with weak (d), moderate (e) or strong (f)TRPM4 positivity</s></p></div></figDesc><graphic coords="5,178.02,54.88,366.65,413.29" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig. 2</head><label>2</label><figDesc><div><p><s>Fig. 2 TRPM4 expression in prostate tissues at protein level.</s><s>Illustration of the progression of TRPM4 expression from normal tissue through PIN to invasive carcinoma.</s><s>Immunohistochemical data from observer 1 (left-most columns) and observer 2 (right-most columns)</s></p></div></figDesc><graphic coords="7,178.02,54.88,366.65,249.00" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><head></head><label></label><figDesc><div><p></p></div></figDesc><graphic coords="9,177.90,54.88,366.64,492.78" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s>Demographic and clinical characteristics of 614 men who underwent radical prostatectomy</s></p></div></figDesc><table><row><cell>Study</cell></row><row><cell>population</cell></row><row><cell>n=614</cell></row></table><note><p><s>GS Gleason score, PSA prostate specific antigen, RP radical prostatectomyInterobserver variation in TRPM4 intensity scoringAll 614 patients had valid TRPM4 intensity scores for benign and cancerous tissue cores from both observers, whereas 386 patients had two valid PIN TRPM4 intensity scores.</s><s>The interobserver concordance was 89.3, 91.5 and 86.0 % for benign, PIN and tumour TRPM4 intensity, respectively, corresponding to linear weighted Kappa values of 0.566 (95 % CI 0.513-0.620),</s><s>0.789 (95 % CI 0.703-0.875)</s><s>and 0.744 (95 % CI 0.682-0.806)</s><s>(Table</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2</head><label>2</label><figDesc><div><p><s>Interobserver agreement on immunohistochemical staining intensity of TRPM4</s></p></div></figDesc><table><row><cell cols="2">Benign TMA cores</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell cols="2">Observer 2</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>0</cell><cell>1+</cell><cell>2+</cell><cell>3+</cell><cell>Patients eligible</cell><cell>Concordance</cell><cell>Weighted Kappa</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>n=614</cell><cell>89.3 %</cell><cell>0.566</cell></row><row><cell>Observer 1</cell><cell>0</cell><cell>20</cell><cell>3</cell><cell>0</cell><cell>0</cell><cell></cell><cell></cell><cell>(95 % CI 0.513-0.620)</cell></row><row><cell></cell><cell>1+</cell><cell>36</cell><cell>500</cell><cell>12</cell><cell>0</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>2+</cell><cell>0</cell><cell>15</cell><cell>28</cell><cell>0</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>3+</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell></cell><cell></cell><cell></cell></row><row><cell>PIN TMA cores</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell cols="2">Observer 2</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>0</cell><cell>1+</cell><cell>2+</cell><cell>3+</cell><cell>Patients eligible</cell><cell>Concordance</cell><cell>Weighted Kappa</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>n=386</cell><cell>91.5 %</cell><cell>0.789</cell></row><row><cell>Observer 1</cell><cell>0</cell><cell>6</cell><cell>3</cell><cell>0</cell><cell>0</cell><cell></cell><cell></cell><cell>(95 % CI 0.703-0.875)</cell></row><row><cell></cell><cell>1+</cell><cell>0</cell><cell>276</cell><cell>23</cell><cell>0</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>2+</cell><cell>0</cell><cell>6</cell><cell>68</cell><cell>0</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>3+</cell><cell>0</cell><cell>0</cell><cell>1</cell><cell>3</cell><cell></cell><cell></cell><cell></cell></row><row><cell>PCa TMA cores</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell cols="2">Observer 2</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>0</cell><cell>1+</cell><cell>2+</cell><cell>3+</cell><cell>Patients eligible</cell><cell>Concordance</cell><cell>Weighted Kappa</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>n=614</cell><cell>86.0 %</cell><cell>0.744</cell></row><row><cell>Observer 1</cell><cell>0</cell><cell>26</cell><cell>10</cell><cell>1</cell><cell>0</cell><cell></cell><cell></cell><cell>(95 % CI 0.682-0.806)</cell></row><row><cell></cell><cell>1+</cell><cell>0</cell><cell>359</cell><cell>51</cell><cell>0</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>2+</cell><cell>0</cell><cell>18</cell><cell>135</cell><cell>4</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>3+</cell><cell>0</cell><cell>0</cell><cell>2</cell><cell>8</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">PCa TMA cores-H-scores</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell cols="2">Observer 2</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>0-50</cell><cell>51-100</cell><cell>101-150</cell><cell>151-300</cell><cell>Patients eligible</cell><cell>Concordance</cell><cell>Weighted Kappa</cell></row><row><cell>Observer 1</cell><cell>0-50</cell><cell>35</cell><cell>35</cell><cell>11</cell><cell>0</cell><cell>n=614</cell><cell>60.1 %</cell><cell>0.541</cell></row><row><cell></cell><cell>51-100</cell><cell>8</cell><cell>170</cell><cell>102</cell><cell>24</cell><cell></cell><cell></cell><cell>(95 % CI 0.489-0.592)</cell></row><row><cell></cell><cell>101-150</cell><cell>1</cell><cell>12</cell><cell>94</cell><cell>38</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>151-300</cell><cell>0</cell><cell>0</cell><cell>14</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 3</head><label>3</label><figDesc><div><p><s>Demographic and clinical characteristics of 614 men who underwent radical prostatectomy stratified on TRPM4 staining intensity</s></p></div></figDesc><table><row><cell>Observer 1</cell><cell>Low staining intensity</cell><cell>High staining intensity</cell><cell>p -value*</cell></row><row><cell></cell><cell>n =124</cell><cell>n =490</cell><cell></cell></row><row><cell>Age, years, median (range)</cell><cell>63 (45 -73)</cell><cell>62 (43 -74)</cell><cell>0.74</cell></row><row><cell>Preoperative PSA, ng/ml, median (range)</cell><cell>7.3 (2.4 -30.4)</cell><cell>7.2 (0.8 -39.0)</cell><cell>0.20cxx</cell></row><row><cell>RP specimen Gleason score, no. (%)</cell><cell></cell><cell></cell><cell>0.58</cell></row><row><cell>GS 6</cell><cell>40 (32.3)</cell><cell>179 (36.5)</cell><cell></cell></row><row><cell>GS 7</cell><cell>63 (50.8)</cell><cell>224 (45.7)</cell><cell></cell></row><row><cell>GS 8 -10</cell><cell>21 (16.9)</cell><cell>87 (17.8)</cell><cell></cell></row><row><cell>Pathological tumour stage, no. (%)</cell><cell></cell><cell></cell><cell>0.27</cell></row><row><cell>pT2</cell><cell>81 (65.3)</cell><cell>345 (70.4)</cell><cell></cell></row><row><cell>pT3 / pT4</cell><cell>43 (34.7)</cell><cell>145 (29.6)</cell><cell></cell></row><row><cell>Tumour in resection margin, no. (%)</cell><cell></cell><cell></cell><cell>0.86</cell></row><row><cell>No (R-)</cell><cell>90 (73.2)</cell><cell>354 (72.4)</cell><cell></cell></row><row><cell>Yes (R+)</cell><cell>33 (26.8)</cell><cell>135 (27.6)</cell><cell></cell></row><row><cell>Observer 2</cell><cell>Low staining intensity</cell><cell>High staining intensity</cell><cell></cell></row><row><cell></cell><cell>n =292</cell><cell>n =322</cell><cell></cell></row><row><cell>Age, years, median (range)</cell><cell>63 (43 -73)</cell><cell>62 (43 -74)</cell><cell>0.99</cell></row><row><cell>Preoperative PSA, ng/ml, median (range)</cell><cell>7.1 (1.0 -39.0)</cell><cell>7.3 (0.8 -38.0)</cell><cell>0.82</cell></row><row><cell>RP specimen Gleason score, no. (%)</cell><cell></cell><cell></cell><cell>0.32</cell></row><row><cell>GS 6</cell><cell>112 (38.4)</cell><cell>107 (33.2)</cell><cell></cell></row><row><cell>GS 7</cell><cell>134 (45.9)</cell><cell>153 (47.5)</cell><cell></cell></row><row><cell>GS 8 -10</cell><cell>46 (15.8)</cell><cell>62 (19.3)</cell><cell></cell></row><row><cell>Pathological tumour stage, no. (%)</cell><cell></cell><cell></cell><cell>0.67</cell></row><row><cell>pT2</cell><cell>205 (70.2)</cell><cell>221 (68.6)</cell><cell></cell></row><row><cell>pT3 / pT4</cell><cell>87 (29.8)</cell><cell>101 (31.4)</cell><cell></cell></row><row><cell>Tumour in resection margin, no. (%)</cell><cell></cell><cell></cell><cell>0.40</cell></row><row><cell>No (R-)</cell><cell>215 (74.1)</cell><cell>229 (71.1)</cell><cell></cell></row><row><cell>Yes (R+)</cell><cell>75 (25.9)</cell><cell>93 (28.9)</cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 4</head><label>4</label><figDesc><div><p><s>Univariate and multiple Cox proportional hazard regression models for risk of biochemical recurrence after radical prostatectomy 'overexpressed and high staining intensity').</s><s>Model B includes the same combined variable for observer 2. High indicates TRPM4 staining intensity equal to or above median H-score.</s><s>Low indicates TRPM4 staining intensity bellow median H-score.</s><s>Not overexpressed indicates staining intensity in prostate cancer glands equal to or bellow benign glands.</s><s>Overexpressed indicates staining intensity in prostate cancer glands above benign glands GS Gleason score, PSA prostate specific antigen, pT pathological tumour stage, ref reference</s></p></div></figDesc><table><row><cell>Fig. 3 Kaplan-Meier estimated</cell></row><row><cell>biochemical recurrence free</cell></row><row><cell>survival curves for 576 patients</cell></row><row><cell>with available biochemical</cell></row><row><cell>follow-up data. a Patients are</cell></row><row><cell>stratified into three groups</cell></row><row><cell>according to observer 1'srecords</cell></row><row><cell>on TRPM4 overexpression in</cell></row><row><cell>PCa compared to benign tissue</cell></row><row><cell>and H-scores. b Patients are</cell></row><row><cell>stratified into three groups</cell></row><row><cell>according to observer 2'srecords</cell></row><row><cell>on TRPM4 overexpression in</cell></row><row><cell>PCa compared to benign tissue</cell></row><row><cell>and H-scores. BR-free survival</cell></row><row><cell>biochemical recurrence free</cell></row><row><cell>survival</cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Virchows Arch (2016) 468:345-355</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Acknowledgement The excellent technical support by Silvia Behnke (immunohistochemistry) is gratefully acknowledged.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Compliance with ethical standard</head><p><s>Financial disclosure/Conflict of Interest None.</s></p></div>
			</div>

			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">European cancer mortality predictions for the year 2014</title>
		<author>
			<persName><forename type="first">M</forename><surname>Malvezzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Bertuccio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Levi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">C</forename><surname>La</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Negri</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="1650" to="1656" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, populationbased study</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Rider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Sandin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Andren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Wiklund</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hugosson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Stattin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Urol</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="88" to="96" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">An updated catalog of prostate cancer predictive tools</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">F</forename><surname>Shariat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">I</forename><surname>Karakiewicz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">G</forename><surname>Roehrborn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Kattan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">113</biblScope>
			<biblScope unit="page" from="3075" to="3099" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer</title>
		<author>
			<persName><forename type="first">M</forename><surname>Fraser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Berlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Bristow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Van Der Kwast</surname></persName>
		</author>
		<author>
			<persName><surname>Genomic</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Urol Oncol</title>
		<imprint>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">A unified nomenclature for the superfamily of TRP cation channels</title>
		<author>
			<persName><forename type="first">C</forename><surname>Montell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Birnbaumer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Flockerzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Bindels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Bruford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Caterina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Clapham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Harteneck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Heller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Julius</forename><forename type="middle">D</forename><surname>Kojima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Mori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Penner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Prawitt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Scharenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Schultz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Shimizu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">X</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Cell</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="229" to="231" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">TRP channels in prostate cancer: the good, the bad and the ugly?</title>
		<author>
			<persName><forename type="first">D</forename><surname>Gkika</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Prevarskaya</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Asian J Androl</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="673" to="676" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<monogr>
		<title level="m" type="main">TRP-Channels and Human Prostate Carcinogenesis. In: Spiess PE (ed) Prostate Cancer -From Bench to Bedside</title>
		<author>
			<persName><forename type="first">V</forename><surname>Lehen'kyi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Prevarskaya</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2011">2011</date>
			<publisher>InTech</publisher>
			<biblScope unit="page" from="133" to="142" />
			<pubPlace>Rijeka</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Differential role of transient receptor potential channels in Ca2+ entry and proliferation of prostate cancer epithelial cells</title>
		<author>
			<persName><forename type="first">S</forename><surname>Thebault</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Flourakis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Vanoverberghe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Vandermoere</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Roudbaraki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Lehen'kyi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Slomianny</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Beck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Mariot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Bonnal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Mauroy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Shuba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Capiod</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Skryma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Prevarskaya</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="2038" to="2047" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Ca2+ homeostasis and apoptotic resistance of neuroendocrine-differentiated prostate cancer cells</title>
		<author>
			<persName><forename type="first">K</forename><surname>Vanoverberghe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Vanden Abeele</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Mariot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Lepage</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Roudbaraki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Bonnal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Mauroy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Shuba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Skryma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Prevarskaya</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell Death Differ</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="321" to="330" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">TRPM8 in prostate cancer cells: a potential diagnostic and prognostic marker with a secretory function</title>
		<author>
			<persName><forename type="first">L</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Barritt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Endocr Relat Cancer</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="27" to="38" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">TRP channels in cancer</title>
		<author>
			<persName><forename type="first">N</forename><surname>Prevarskaya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Barritt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochim Biophys Acta</title>
		<imprint>
			<biblScope unit="volume">1772</biblScope>
			<biblScope unit="page" from="937" to="946" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<monogr>
		<title level="m" type="main">Transient Receptor Potential Cation Channels -Handbook of Experimental Pharmacology</title>
		<author>
			<persName><forename type="first">I</forename><surname>Mathar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Jacobs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kecskes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Menigoz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Philippaert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Vennekens</surname></persName>
		</author>
		<editor>Nilius B, Flockerzi V</editor>
		<imprint>
			<date type="published" when="2014">2014</date>
			<publisher>Springer</publisher>
			<biblScope unit="page" from="461" to="487" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Tissue distribution profiles of the human TRPM cation channel family</title>
		<author>
			<persName><forename type="first">E</forename><surname>Fonfria</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename><surname>Murdock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">S</forename><surname>Cusdin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Benham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Kelsell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mcnulty</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Recept Signal Transduct Res</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="159" to="178" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Expression profiling of microdissected matched prostate cancer samples reveals CD166/ MEMD and CD24 as new prognostic markers for patient survival</title>
		<author>
			<persName><forename type="first">G</forename><surname>Kristiansen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Pilarsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Wissmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kaiser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Bruemmendorf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Roepcke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Dahl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Hinzmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Specht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Pervan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Stephan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Loening</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dietel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rosenthal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Pathol</title>
		<imprint>
			<biblScope unit="volume">205</biblScope>
			<biblScope unit="page" from="359" to="376" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">TRPM4 enhances cell proliferation through upregulation of the beta-catenin signaling pathway</title>
		<author>
			<persName><forename type="first">R</forename><surname>Armisen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Marcelain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Simon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Tapia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Toro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">F</forename><surname>Quest</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Stutzin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cell Physiol</title>
		<imprint>
			<biblScope unit="volume">226</biblScope>
			<biblScope unit="page" from="103" to="109" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics</title>
		<author>
			<persName><forename type="first">G</forename><surname>Kristiansen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">R</forename><surname>Fritzsche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Wassermann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Jager</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tolls</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Stephan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Jung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Pilarsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dietel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Moch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Cancer</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="page" from="939" to="948" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Automated quantitation of immunocytochemically localized estrogen receptors in human breast cancer</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Mcclelland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Finlay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Walker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Nicholson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Robertson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Blamey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">I</forename><surname>Nicholson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page" from="3545" to="3550" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Molecular features of the transition from prostatic intraepithelial neoplasia (PIN) to prostate cancer: genome-wide gene-expression profiles of prostate cancers and PINs</title>
		<author>
			<persName><forename type="first">S</forename><surname>Ashida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Nakagawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Katagiri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Furihata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Iiizumi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Anazawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Tsunoda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Takata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kasahara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Miki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Fujioka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Shuin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Nakamura</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="5963" to="5972" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells</title>
		<author>
			<persName><forename type="first">P</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ramachandran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Ali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Scharer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Laycock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">B</forename><surname>Dalton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Williams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Karanam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Datta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Jaye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Moreno</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="4011" to="4019" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Annotation of androgen dependence to human prostate cancer-associated genes by microarray analysis of mouse prostate</title>
		<author>
			<persName><forename type="first">J</forename><surname>Singh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Manickam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Shmoish</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Natik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Denyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Handelsman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Gong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Dong</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Lett</title>
		<imprint>
			<biblScope unit="volume">237</biblScope>
			<biblScope unit="page" from="298" to="304" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">TRPM4 is a Ca2+-activated nonselective cation channel mediating cell membrane depolarization</title>
		<author>
			<persName><forename type="first">P</forename><surname>Launay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Fleig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Perraud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Scharenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Penner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Kinet</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">109</biblScope>
			<biblScope unit="page" from="397" to="407" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Voltage dependence of the Ca2+-activated cation channel TRPM4</title>
		<author>
			<persName><forename type="first">B</forename><surname>Nilius</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Prenen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Droogmans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Voets</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Vennekens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Freichel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Wissenbach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Flockerzi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">278</biblScope>
			<biblScope unit="page" from="30813" to="30820" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Comparison of functional properties of the Ca2 + -activated cation channels TRPM4 and TRPM5 from mice</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">D</forename><surname>Ullrich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Voets</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Prenen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Vennekens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Talavera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Droogmans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Nilius</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell Calcium</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="267" to="278" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">The selectivity filter of the cation channel TRPM4</title>
		<author>
			<persName><forename type="first">B</forename><surname>Nilius</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Prenen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Janssens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Owsianik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">X</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Voets</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">280</biblScope>
			<biblScope unit="page" from="22899" to="22906" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Critical role for transient receptor potential channel TRPM4 in myogenic constriction of cerebral arteries</title>
		<author>
			<persName><forename type="first">S</forename><surname>Earley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Waldron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Brayden</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circ Res</title>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="page" from="922" to="929" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">The TRPM4 non-selective cation channel contributes to the mammalian atrial action potential</title>
		<author>
			<persName><forename type="first">C</forename><surname>Simard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hof</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Keddache</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Launay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Guinamard</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Mol Cell Cardiol</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="11" to="19" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Transient receptor potential melastatin 4 inhibition prevents lipopolysaccharideinduced endothelial cell death</title>
		<author>
			<persName><forename type="first">A</forename><surname>Becerra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Echeverria</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Varela</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Sarmiento</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Armisen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Nunez-Villena</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Montecinos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Simon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cardiovasc Res</title>
		<imprint>
			<biblScope unit="volume">91</biblScope>
			<biblScope unit="page" from="677" to="684" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Expression profiling analysis of the CD5+ diffuse large B-cell lymphoma subgroup: development of a CD5 signature</title>
		<author>
			<persName><forename type="first">M</forename><surname>Suguro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Tagawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Kagami</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Okamoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ohshima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Shiku</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Morishima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Nakamura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Seto</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Sci</title>
		<imprint>
			<biblScope unit="volume">97</biblScope>
			<biblScope unit="page" from="868" to="874" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Beta-catenin-a linchpin in colorectal carcinogenesis?</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pignatelli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">160</biblScope>
			<biblScope unit="page" from="389" to="401" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">The Wnt signaling pathway in development and disease</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">Y</forename><surname>Logan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Nusse</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Annu Rev Cell Dev Biol</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="781" to="810" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Multiple tumor marker analyses (PSA, hK2, PSCA, trp-p8) in primary prostate cancers using quantitative RT-PCR</title>
		<author>
			<persName><forename type="first">S</forename><surname>Fuessel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Sickert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Meye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Klenk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Schmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schmitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Rost</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Weigle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kiessling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Wirth</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Oncol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="221" to="228" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancerassociated protein trp-p8</title>
		<author>
			<persName><forename type="first">A</forename><surname>Kiessling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Fussel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schmitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Stevanovic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Meye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Weigle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Klenk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Wirth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Rieber</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Prostate</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="270" to="279" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Henshall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Afar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hiller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">G</forename><surname>Horvath</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">I</forename><surname>Quinn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">K</forename><surname>Rasiah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Gish</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Willhite</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Kench</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gardiner-Garden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Stricker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">I</forename><surname>Scher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Grygiel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Agus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Mack</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Sutherland</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="4196" to="4203" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">CaT1 expression correlates with tumor grade in prostate cancer</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Peng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zhuang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">V</forename><surname>Berger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Adam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Williams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Hediger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Freeman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochem Biophys Res Commun</title>
		<imprint>
			<biblScope unit="volume">282</biblScope>
			<biblScope unit="page" from="729" to="734" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Expression of the Ca2 + -selective cation channel TRPV6 in human prostate cancer: a novel prognostic marker for tumor progression</title>
		<author>
			<persName><forename type="first">T</forename><surname>Fixemer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Wissenbach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Flockerzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Bonkhoff</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncogene</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="7858" to="7861" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">S</forename><surname>Antonarakis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Feng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Trock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">B</forename><surname>Humphreys</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Carducci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">W</forename><surname>Partin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Walsh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Eisenberger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BJU Int</title>
		<imprint>
			<biblScope unit="volume">109</biblScope>
			<biblScope unit="page" from="32" to="39" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">The impact of the number of cores on tissue microarray studies investigating prostate cancer biomarkers</title>
		<author>
			<persName><forename type="first">P</forename><surname>Tennstedt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Koster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bruchmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mirlacher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Haese</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Steuber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Sauter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Huland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Graefen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Schlomm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Minner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Simon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Oncol</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="261" to="268" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Observer variation in immunohistochemical analysis of protein expression</title>
		<author>
			<persName><forename type="first">T</forename><surname>Kirkegaard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Edwards</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Tovey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Mcglynn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">N</forename><surname>Krishna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Mukherjee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Tam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">F</forename><surname>Munro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Dunne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Bartlett</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Histopathology</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="787" to="794" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">The measurement of observer agreement for categorical data</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Landis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">G</forename><surname>Koch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biometrics</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="159" to="174" />
			<date type="published" when="1977">1977</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
